WuXi Biologics and Sinorda Biomedicine have jointly announced a strategic collaboration for the development and manufacturing of SND006.

On January 14, Dr. Chris Chen, CEO of WuXi Biologics, delivered a keynote at the 44th J.P. Morgan Healthcare Conference, ...

HanchorBio and WuXi Biologics collaborate to develop fusion proteins using the Fc-Based Designer Biologics platform, targeting oncology and autoimmune diseases. WuXi Biologics offers end-to-end ...

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and ...

WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and ...

China-based biologics services group WuXi Biologics (HKG: 2269) has entered a strategic collaboration with Sinorda ...

The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces viscosity by up to 90% while maintaining formulation ...

WUXI, China, March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic ...

Taiwanese biotech HanchorBio (TPEx: 7827) has signed a strategic collaboration with WuXi Biologics (HKEX: 2269) to develop ...

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO ...

WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development and manufacturing of innovative bispecific antibody: Shanghai Friday, January 30, 2026, 10:00 Hrs [IST ...